Atalay G, Cardoso F, Awada A, Piccart M J
Jules Bordet Institute, Department of Medical Oncology, Brussels, Belgium.
Ann Oncol. 2003 Sep;14(9):1346-63. doi: 10.1093/annonc/mdg365.
From the early experience with tamoxifen to the current use of Herceptin, targeted therapy has been proven to be an important part of breast cancer (BC) treatment. In the last decade, advances in molecular biology have allowed scientists to design highly individualized, 'smart' pharmaceuticals, capable of manipulating the growth factor pathways and the genes that are involved in the development and maintenance of the malignant phenotype. The epidermal growth factor receptor (EGFR) family, as one of the best studied growth factor pathways in cancer, resembles a 'treasure island' by providing a wide range of biologically relevant targets involved in breast carcinogenesis. While a large number of new agents targeting this pathway are continuingly being tested in preclinical experiments, clinicians are witnessing the migration of some of these agents to daily practice. The aim of this review is to provide clinicians with an updated synopsis of the most advanced anti-erbB therapeutic strategies with activity against BC.
从他莫昔芬的早期应用到如今赫赛汀的使用，靶向治疗已被证明是乳腺癌（BC）治疗的重要组成部分。在过去十年中，分子生物学的进展使科学家能够设计出高度个体化的“智能”药物，这些药物能够操纵生长因子通路以及参与恶性表型发展和维持的基因。表皮生长因子受体（EGFR）家族作为癌症中研究最为深入的生长因子通路之一，通过提供广泛参与乳腺癌发生的生物学相关靶点，宛如一座“宝岛”。虽然大量针对该通路的新型药物仍在临床前实验中不断接受测试，但临床医生正目睹其中一些药物进入日常临床应用。本综述的目的是为临床医生提供针对BC具有活性的最先进抗erbB治疗策略的最新概述。
